PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

STEMCELL Technologies, Inc. to Launch TeSR-E8 - A New Product to Advance Research on Human Pluripotent Stem Cells - STEMCELL Technologies, Inc. to Launch TeSR-E8 - a Novel Medium for Human Embryonic and Induced Pluripotent Stem Cells - and New STEMdiff Kits for Differentiation of these cell types - WARF.org / Stemcell.com
STEMCELL Technologies, Inc. to Launch TeSR-E8 - A New Product to Advance Research on Human Pluripotent Stem Cells

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2012/06/18 - STEMCELL Technologies, Inc. to Launch TeSR-E8 - a Novel Medium for Human Embryonic and Induced Pluripotent Stem Cells - and New STEMdiff Kits for Differentiation of these cell types - WARF.org / Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

STEMCELL Technologies, Inc. (STEMCELL) announced today its plans to release a series of new products to advance research and translational applications for human pluripotent stem cells.

These novel products, which will be launched at the International Society for Stem Cell Research 2012 Conference in Japan, include:

TeSR™-E8™: a highly defined feeder-free culture medium for human embryonic stem cells (ES cells) and human induced pluripotent stem cells (iPS cells). TeSR-E8 contains only the most essential 8 components required for maintenance of ES cells and iPS cells, providing a simpler medium for the culture of pluripotent stem cells. It is based on the E8 formulation published in Nature Methods (G. Chen et al., Nature Methods 8, 424 (2011)). This lab previously developed the mTeSR™1 and TeSR™2 feeder-free culture media, which were licensed and commercialized by STEMCELL Technologies and are now the most widely-published feeder-free culture media for human pluripotent stem cells. TeSR-E8 can be used with a surface coating of BD Matrigel™ hESC-qualified Matrix or vitronectin, as described in this publication. It will be available for purchase in September 2012 under the license agreement that STEMCELL has with the Wisconsin Alumni Research Foundation (WARF).

STEMdiff™ Definitive Endoderm / Cardiomyocyte / Hematopoietic kits: the STEMdiff product line is significantly expanded with the world’s first complete commercial kits for directed hPSC differentiation to definitive endoderm, cardiomyocyte and hematopoietic lineages. These new kits will be available for purchase in October 2012. STEMdiff products provide robust reagents and protocols to reliably differentiate hPSC to various lineages and are optimized for use with mTeSR™1 and TeSR™2 feeder-free culture media.

“We are delighted to build on our track record for providing high quality cell culture media to stem cell scientists, by introducing new products that work as an integrated system,” said Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “We are excited to give scientists products that are designed to work together and extend from reprogramming through to differentiation.”

By adding TeSR-E8 and the new STEMdiff kits to its portfolio, STEMCELL Technologies continues to provide the most complete, defined system of integrated tools for human pluripotent stem cell research. These high-quality reagents for defined pluripotent cell culture increase experimental reproducibility, eliminate variable biologic elements in the culture media and increase clinical relevance for culture of ES cells and iPS cells.

About STEMCELL Technologies, Inc.

STEMCELL Technologies, Inc. (stemcell.com) is a leader in the development and marketing of specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 1000 products to research scientists in more than 70 countries worldwide.

About WARF

Since its founding in 1925 to manage a University of Wisconsin–Madison discovery that eventually eliminated the childhood disease rickets, the Wisconsin Alumni Research Foundation has been working with industry to transform university research into products that benefit society. As a private, nonprofit organization, WARF (WARF.org) accomplishes its mission of supporting scientific research by patenting and licensing inventions arising from university discoveries. Since making its first grant of $1,200 in 1928, WARF has contributed more than $1 billion to UW–Madison through annual "margin of excellence'' grants and other funding.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies, Inc. to Launch TeSR-E8 - A New Product to Advance Research on Human Pluripotent Stem Cells

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

STEMCELL Technologies |
Publisher Contact: Simon Hilcove - Stemcell.com 
604-877-0713 marketing[.]stemcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)